

**UK And Ireland Neuroendocrine Tumour Society Limited**

**Charity No. 1148145**

**Company No. 06672185**

**Trustees' Report and Unaudited Accounts**

**31 August 2025**

Registered Address:

Starling House  
Unit 1600 Bristol Parkway North  
Bradley Stoke  
Bristol  
BS34 8YU

**UK And Ireland Neuroendocrine Tumour Society Limited**  
**Contents**

	Pages
Trustees' Annual Report	2 to 6
Independent Examiner's Report	7
Statement of Financial Activities	8 to 9
Balance Sheet	10
Notes to the Accounts	11 to 15
Detailed Statement of Financial Activities	16 to 17

The trustees, who are also directors of the charity for the purposes of the Companies Act 2006, present their report and unaudited financial statements of the charity for the year ending 31 August 2025.

### **Trustees**

The trustees, who are also the directors for the purposes of company law, and who served during the year and up to the date of signature of the unaudited financial statements were:

Prof T H Shah

Prof C Thirlwell – resigned 2 December 2024

Prof M Pritchard

Prof R Srirajaskanthan

Dr A Munir – appointed 2 December 2024

None of the directors has any beneficial interest in the company. All of the trustees are members of the company and guarantee to contribute £1 in the event of winding up.

### **Governing document**

The UK and Ireland Neuroendocrine Tumour Society Limited (UKI NETS) is constituted by its Memorandum & Articles of Association, adopted by the membership on 7 December 2015, and is a registered charity. UKI NETS became a company limited by guarantee on 13 August 2008 and was subsequently registered as a charity on 16 July 2012.

### **Organisational structure**

The Society has four main categories of membership as follows: Clinician; Scientist; Nurse and Allied Health Professional Members. Each of these categories is broken down into career stages. All members are given the option of membership with or without inclusive ENETS membership. Membership of the charity is open to any medical professionals or scientists interested in promoting the objects.

The Society is governed by four Executive Officers, who are the directors and trustees (Chair, Past Chair or Chair-elect, Treasurer and Secretary), supported by a wider Executive Committee, which includes chairs of the sub committees. All Executive Officers and Executive Committee members are elected by member ballot.

### **Risk management**

The trustees have a duty to identify and review the risks to which the charity is exposed and to ensure appropriate controls are in place to provide reasonable assurance against fraud and error.

## **Objectives and activities**

The charity's objects are to promote for the public benefit research, education and clinical practice in neuroendocrine tumours by the organisation of conferences, training courses and publications, by raising public awareness, liaison with national and international legislators, and by any other appropriate means. The Society aims to improve the diagnosis and therapy of patients with neuroendocrine tumours within a national multidisciplinary and scientific context.

In furtherance of its objects, the Society shall have the following powers:

1. To arrange and provide for the holding of meetings, lectures and seminars.
2. To procure to be written and print, publish, issue and circulate gratuitously or otherwise such papers, periodicals, pamphlets or other documents.
3. To raise funds and to invite and receive contributions from any person or persons whatsoever by way of subscriptions and otherwise provided that the Society shall not undertake any permanent trading activities in raising funds for its primary charitable objectives.
4. To co-operate, associate or affiliate with any other charitable institutions.
5. To do all such other lawful things as are necessary for the attainment of the above objectives.

The summary of main activities in relation to the charity objectives are as follows:

- Annual Scientific Meeting
- Provision of travel grants
- Provision of meeting awards
- Allocation of research grants provided by Neuroendocrine Cancer UK
- Provision of educational activities (webinars and NET for Newcomers training day)
- Guideline development
- Public/healthcare professional engagement in association with Neuroendocrine Cancer UK
- Promotion of research

All trustees have had regard to the Charity Commission's guidance on public benefit when planning for the Society's activities.

## **Achievements and performance**

### **UKI NETS 22nd Annual Conference: Cardiff**

The 22<sup>nd</sup> Annual Conference of the Society was held at Mercure Holland House Hotel in Cardiff on Monday 2 December 2024.

The programme contained sessions focused on: Multi-Disciplinary Challenges in Clinical Practice; a clinical trials overview; immunotherapy in patients with high grade NENs; recent developments in PRRT; MEN Syndromes and Challenges; a NET translational medicine session and a NET nurses' session. Posters and oral communications were presented. The conference ended with a Prize Giving session and a lifetime achievement award was presented during the day. Satellite symposia were also held by sponsors.

## **Provision of travel grants**

Five travel grants were awarded to the presenters of the best scoring abstracts for the conference (excluding physicians in post more than 5 years). Four were awarded free membership for a year; one current member was awarded £100.

## **Provision of meeting awards**

Prizes were awarded to the top three best scoring clinical and scientific posters and the best oral communication at the 22<sup>nd</sup> Annual Conference.

## **Provision of Research grants**

Neuroendocrine Cancer UK (NCUK), in association with UKINETS, awarded two pump priming grants of £25k each to provide pump-priming funds to support research projects designed to improve outcomes for patients with neuroendocrine cancer.

## **Public Engagement**

UKI NETS members have been involved with and supporting the Neuroendocrine Cancer UK awareness campaign for healthcare professionals, 'Spotlight on Neuroendocrine Cancer', developing NET overviews for those who see NET patients but are not experts.

## **Educational activities**

NETs for Newcomers:

On 9<sup>th</sup> May 2025 UKINETS presented the eighth annual one day course for doctors and HCPs of all specialties who wished to learn more about Neuroendocrine Tumours. It was held face to face in Manchester. The course was delivered by an expert multidisciplinary faculty and included a 'mock MDT' practice in small groups. Approximately 34 HCPs attended and feedback was very positive. 6 CPD points were awarded to attendees.

Webinars:

UKINETS continued to deliver its series of educational webinars, led by the Education and Training Committee. Webinars were delivered on NET oncology and theragnostics. The webinars are free to attend for both members and non-members of UKINETS.

## **Guideline development**

The UKINETS Clinical Practice Committee continues to create clinical guideline documents for its Bitesize Guidance library, available on the UKINETS website. As well as the creation of new guidance, existing guidance was reviewed and updated.

## **Dietitians' Working Group**

The AHP/Dietitian representative on the Executive Committee also chairs the UKINETS Dietitians' Working Group. The group delivered a teaching session for dietitians and nurses, compiled data from UK Centre of Excellence NET centres on dietitian support (or lack of) for the NET MDT and began planning a NET nutrition study day for early 2026.

## **Sponsor Support**

There was financial support to the Society in the form of sponsorship from pharmaceutical and technology companies with products relevant to NETs. The majority of the funding was provided as sponsorship for the National Conference and NETs for Newcomers Training Day.

## **Website**

The charity's website provides an important tool to inform members and the general public about the activities of the Society, as well as updates in NET research. <http://www.ukinets.org>.

## **Communications**

UKI NETS communicates with its members by means of an e-newsletter delivering news from the Society and the wider field. In addition, the charity highlights on its website news and research relating to the field of neuroendocrine tumours. The charity also has its own X account @UKINETS. The Society is in the process of investigating the use of other social networks.

## **Clinical Trials and Research Development**

UKINETS includes a summary of recent clinical trials related to NETs on its website and at its annual scientific conference.

UKINETS has continued to manage a project to set up a national database for NETs to facilitate valuable future research.

## **Link with the European Neuroendocrine Tumour Society (ENETS)**

UKI NETS continues to provide optional inclusive membership to its members to its European partner Society, ENETS. Through membership of ENETS, UKI NETS members have access to *Journal of Neuroendocrinology* and a reduced rate for the ENETS annual conference. A member of UKINETS sits on the Executive Committee of ENETS.

## **Financial review**

### **Principal funding sources**

Income to the Society is mainly generated through industry support, the annual conference and membership subscriptions. Personal donations/legacies are received on an ad hoc basis.

### **Reserves policy**

The reserve policy takes into consideration the major risks that could face the Society.

It is the policy of the Society to maintain unrestricted funds, which are the free reserves of the charity. The reserves are held at a level that ensures the financial viability of the Society. That level is currently deemed to be one that equates to a minimum of two years' expenditure. The officers of the Society will be reviewing this policy to ensure it still fit for purpose. The balance sheet indicates that there are £168,917 unrestricted funds as at 31 August 2025. This provides sufficient funds to cover management, administration and support costs.


### Plans for future periods

The UKI NETS 23<sup>rd</sup> Annual Conference is scheduled to be held in London in December 2025, with abstracts submitted and posters and oral communications presented as usual.

Other plans for the coming year include:

- Holding a NET Nutrition Study Day in January 2026
- Awarding 3 x Pump Priming Grants and 2 x Practice Changing grants on behalf of NCUK in February 2026
- Holding a further NETs for Newcomers training event in Sheffield in June 2026
- Further developing the library of bite size clinical guidance for the website
- Continuing the delivery of a programme of free educational webinars on varied topics relating to NETs – to improve education and awareness for HCPs, possibly collaborating with partners to deliver more
- Continuing to plan and deliver a national NET database for research purposes
- Collaborating with NCUK to manage the Neuroendocrine Cancer Priority Setting Partnership with the James Lind Alliance
- Endorsement of 'Bronchopulmonary Carcinoids unveiled' (a workshop delivered by the Christie) in January 2026
- Providing feedback on external clinical guidelines where appropriate
- Continuing to secure funding from corporate donors
- Continuing to develop communications with members

The Trustees Report was approved by the Board of Trustees and signed on its behalf by:



Prof R Srirajaskanthan

Trustee

Dated: 29/2/26

Registered Address:  
Starling House  
1600 Bristol Parkway North  
Bristol  
BS34 8YU

**Independent Examiner's Report to the trustees of UK And Ireland Neuroendocrine Tumour Society Limited**

I report to the charity trustees on my examination of the financial statements of UK And Ireland Neuroendocrine Tumour Society Limited for the year ended 31 August 2025.

**Responsibilities and basis of report**

As the charity's trustees of the company (and also its directors for the purposes of company law) you are responsible for the preparation of the financial statements in accordance with the requirements of the Companies Act 2006 ('the 2006 Act).


Having satisfied myself that the financial statements of the Charity are not required to be audited under Part 16 of the 2006 Act and are eligible for independent examination, I report in respect of my examination of your charity's financial statements as carried out under section 145 of the Charities Act 2011 ('the 2011 Act'). In carrying out my examination I have followed the Directions given by the Charity Commission under section 145(5) (b) of the 2011 Act.

**Independent examiner's statement**

I have completed my examination. I can confirm that no material matters have come to my attention in connection with the examination giving me cause to believe:

- accounting records were not kept in accordance with section 386 of the 2006 Act ; or
- the financial statements do not accord with those records; or
- the financial statements do not comply with the accounting requirements under section 396 of the 2006 Act other than any requirement that the financial statements give a 'true and fair' view which is not a matter considered as part of an independent examination; or
- the financial statements have not been prepared in accordance with the methods and principles of the Statement of Recommended Practice for accounting and reporting by charities applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102).

I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the financial statements to be reached.



Andy Hopkins  
BVSC  
Latham House  
33-34 Paradise Street  
Birmingham

B1 2AJ  
19 January 2026



UK And Ireland Neuroendocrine Tumour Society Limited

Statement of Financial Activities

for the year ended 31 August 2025

		Unrestricted funds 2025 £	Restricted funds 2025 £	Total funds 2025 £	Total funds 2024 £
	Notes				
<b>Income and endowments from:</b>					
Donations and legacies	4	23,526	-	23,526	23,252
Charitable activities	5	104,234	-	104,234	114,228
Other	6	200	-	200	-
<b>Total</b>		<b>127,960</b>	<b>-</b>	<b>127,960</b>	<b>137,480</b>
<b>Expenditure on:</b>					
Charitable activities	7	56,149	5,068	61,217	70,435
Other	8	60,285	-	60,285	51,486
<b>Total</b>		<b>116,434</b>	<b>5,068</b>	<b>121,502</b>	<b>121,921</b>
Net gains on investments		-	-	-	-
<b>Net income</b>	9	<b>11,526</b>	<b>(5,068)</b>	<b>6,458</b>	<b>15,559</b>
Transfers between funds		396	(396)	-	-
<b>Net income before other gains/(losses)</b>		<b>11,922</b>	<b>(5,464)</b>	<b>6,458</b>	<b>15,559</b>
<b>Other gains and losses</b>					
<b>Net movement in funds</b>		<b>11,922</b>	<b>(5,464)</b>	<b>6,458</b>	<b>15,559</b>
<b>Reconciliation of funds:</b>					
Total funds brought forward		156,995	5,464	162,459	146,900
<b>Total funds carried forward</b>		<b>168,917</b>	<b>-</b>	<b>168,917</b>	<b>162,459</b>

UK And Ireland Neuroendocrine Tumour Society Limited  
Summary Income and Expenditure Account  
for the year ended 31 August 2025

	2025 £	2024 £
Income	127,960	137,480
<b>Gross income for the year</b>	<u>127,960</u>	<u>137,480</u>
Expenditure	121,502	121,922
<b>Total expenditure for the year</b>	<u>121,502</u>	<u>121,922</u>
Net income before tax for the year	6,458	15,558
<b>Net income for the year</b>	<u>6,458</u>	<u>15,558</u>

**UK And Ireland Neuroendocrine Tumour Society Limited**

**Balance Sheet**

**at 31 August 2025**

<b>Company No. 06672185</b>	<b>Notes</b>	<b>2025 £</b>	<b>2024 £</b>
<b>Current assets</b>			
Debtors	11	30,447	31,254
Cash at bank and in hand		144,492	137,060
		<u>174,939</u>	<u>168,314</u>
<b>Creditors: Amount falling due within one year</b>	12	(6,022)	(5,855)
<b>Net current assets</b>		<u>168,917</u>	<u>162,459</u>
<b>Total assets less current liabilities</b>		<u>168,917</u>	<u>162,459</u>
<b>Net assets excluding pension asset or liability</b>		<u>168,917</u>	<u>162,459</u>
<b>Total net assets</b>		<u><u>168,917</u></u>	<u><u>162,459</u></u>
<b>The funds of the charity</b>			
<b>Restricted funds</b>	13		
Restricted income funds		-	5,464
		<u>-</u>	<u>5,464</u>
<b>Unrestricted funds</b>	13		
General funds		168,917	156,995
		<u>168,917</u>	<u>156,995</u>
<b>Reserves</b>	13		
<b>Total funds</b>		<u><u>168,917</u></u>	<u><u>162,459</u></u>

These accounts have been prepared in accordance with the special provisions of Part 15 of the Companies Act 2006 relating to small companies.


For the year ended 31 August 2025 the company was entitled to exemption under section 477 of the Companies Act 2006 relating to small companies.

The members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of accounts.

Approved by the board on 13 February 2026

And signed on its behalf by:



R. Srirajaskanthan

Trustee

Date: 24/2/2026.

## 1 Accounting policies

### Basis of preparation

The financial statements have been prepared in accordance with Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2015) - (Charities SORP (FRS 102)), the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) and the Companies Act 2006.

### Change in basis of accounting or to previous accounts

There has been no change to the accounting policies (valuation rules and method of accounting) since last year and no changes have been made to accounts for previous years.

### Fund accounting

Unrestricted funds	These are available for use at the discretion of the trustees in furtherance of the general objects of the charity.
Designated funds	These are unrestricted funds earmarked by the trustees for particular purposes.
Revaluation funds	These are unrestricted funds which include a revaluation reserve representing the restatement of investment assets at their market values.
Restricted funds	These are available for use subject to restrictions imposed by the donor or through terms of an appeal.

### Income

Recognition of income	Income is included in the Statement of Financial Activities (SoFA) when the charity becomes entitled to, and virtually certain to receive, the income and the amount of the income can be measured with sufficient reliability.
Income with related expenditure	Where income has related expenditure the income and related expenditure is reported gross in the SoFA.
Donations and legacies	Voluntary income received by way of grants, donations and gifts is included in the the SoFA when receivable and only when the Charity has unconditional entitlement to the income.
Tax reclaims on donations and gifts	Income from tax reclaims is included in the SoFA at the same time as the gift/donation to which it relates.
Donated services and facilities	These are only included in income (with an equivalent amount in expenditure) where the benefit to the Charity is reasonably quantifiable, measurable and material.
Volunteer help	The value of any volunteer help received is not included in the accounts.
Investment income	This is included in the accounts when receivable.
Gains/(losses) on revaluation of fixed assets	This includes any gain or loss resulting from revaluing investments to market value at the end of the year.
Gains/(losses) on investment assets	This includes any gain or loss on the sale of investments.

Notes to the Accounts

**Expenditure**

Recognition of expenditure	Expenditure is recognised on an accruals basis. Expenditure includes any VAT which cannot be fully recovered, and is reported as part of the expenditure to which it relates.
Expenditure on raising funds	These comprise the costs associated with attracting voluntary income, fundraising trading costs and investment management costs.
Expenditure on charitable activities	These comprise the costs incurred by the Charity in the delivery of its activities and services in the furtherance of its objects, including the making of grants and governance costs.
Grants payable	All grant expenditure is accounted for on an actual paid basis plus an accrual for grants that have been approved by the trustees at the end of the year but not yet paid.
Governance costs	These include those costs associated with meeting the constitutional and statutory requirements of the Charity, including any audit/independent examination fees, costs linked to the strategic management of the Charity, together with a share of other administration costs.
Other expenditure	These are support costs not allocated to a particular activity.

**Taxation**

The charity is exempt from corporation tax on its charitable activities.

**Trade and other debtors**

Trade and other debtors are recognised at the settlement amount due after any trade discount offered. Prepayments are valued at the amount prepaid net of any trade discounts due.

**2 Company status**

The company is a private company limited by guarantee and consequently does not have share capital.

3 Statement of Financial Activities - prior year

	Unrestricted funds 2024 £	Restricted funds 2024 £	Total funds 2024 £
<b>Income and endowments from:</b>			
Donations and legacies	23,252	-	23,252
Charitable activities	114,228	-	114,228
<b>Total</b>	<b>137,480</b>	<b>-</b>	<b>137,480</b>
<b>Expenditure on:</b>			
Charitable activities	121,922	-	121,922
<b>Total</b>	<b>121,922</b>	<b>-</b>	<b>121,922</b>
<b>Net income</b>	<b>15,558</b>	<b>-</b>	<b>15,558</b>
<b>Net income before other gains/(losses)</b>	<b>15,558</b>	<b>-</b>	<b>15,558</b>
<b>Other gains and losses:</b>			
<b>Net movement in funds</b>	<b>15,558</b>	<b>-</b>	<b>15,558</b>
<b>Reconciliation of funds:</b>			
Total funds brought forward	141,436	5,464	146,900
<b>Total funds carried forward</b>	<b>156,994</b>	<b>5,464</b>	<b>162,458</b>

4 Income from donations and legacies

	Unrestricted £	Total 2025 £	Total 2024 £
Donations and gifts	2,064	2,064	4,350
Membership Fees	21,462	21,462	18,902
	<b>23,526</b>	<b>23,526</b>	<b>23,252</b>

5 Income from charitable activities

	Unrestricted £	Total 2025 £	Total 2024 £
Sponsorship	104,234	104,234	114,228
	<b>104,234</b>	<b>104,234</b>	<b>114,228</b>

6 Other income

	Unrestricted £	Total 2025 £	Total 2024 £
	200	200	-
	<b>200</b>	<b>200</b>	<b>-</b>

**7 Expenditure on charitable activities**

	Unrestricted	Restricted	Total 2025	Total 2024
	£	£	£	£
<i>Expenditure on charitable activities</i>				
Conferences and newsletters	56,149	-	56,149	70,308
Application development costs	-	5,068	5,068	-
<i>Governance costs</i>				
	-	-	-	127
	<u>56,149</u>	<u>5,068</u>	<u>61,217</u>	<u>70,435</u>

**8 Other expenditure**

	Unrestricted	Total 2025	Total 2024
	£	£	£
Other operating costs	44,623	44,623	37,238
Management and Accountancy	15,662	15,662	14,248
	<u>60,285</u>	<u>60,285</u>	<u>51,486</u>

**9 Net income before transfers**

	2025	2024
	£	£
This is stated after charging:		
Independent Examiner's fee	1,440	1,440

**10 Staff costs**

No employee received emoluments in excess of £60,000.

**11 Debtors**

	2025	2024
	£	£
Other debtors	5,447	-
Prepayments and accrued income	25,000	31,254
	<u>30,447</u>	<u>31,254</u>

**12 Creditors:**

amounts falling due within one year

	2025	2024
	£	£
Accruals	6,022	5,855
	<u>6,022</u>	<u>5,855</u>

## Notes to the Accounts

## 13 Movement in funds

	At 1 September 2024	Incoming resources (including other gains/losses) £	Resources expended £	Gross transfers £	At 31 August 2025 £
<b>Restricted funds:</b>					
<b>Restricted income funds:</b>					
TransNet	5,464	-	(5,068)	(396)	-
<i>Total</i>	<u>5,464</u>	<u>-</u>	<u>(5,068)</u>	<u>(396)</u>	<u>-</u>
<b>Unrestricted funds:</b>					
<b>General funds</b>	156,995	127,960	(116,434)	396	168,917
<b>Total funds</b>	<u>162,459</u>	<u>127,960</u>	<u>(121,502)</u>	<u>-</u>	<u>168,917</u>

Purposes and restrictions in relation to the funds:

Restricted funds:

TransNet

## 14 Analysis of net assets between funds

	Unrestricted funds £	Restricted funds £	Total £
Net current assets	163,470	5,447	168,917
	<u>163,470</u>	<u>5,447</u>	<u>168,917</u>

## 15 Reconciliation of net debt

	At 1 September 2024 £	Cash flows £	At 31 August 2025 £
Cash and cash equivalents	137,060	7,432	144,492
	<u>137,060</u>	<u>7,432</u>	<u>144,492</u>
Net debt	<u>137,060</u>	<u>7,432</u>	<u>144,492</u>

## 16 Related party disclosures

**Controlling party**

The company is limited by guarantee and has no share capital; thus no single party controls the company.



UK And Ireland Neuroendocrine Tumour Society Limited

Detailed Statement of Financial Activities

for the year ended 31 August 2025

	Unrestricted funds 2025 £	Restricted funds 2025 £	Total funds 2025 £	Total funds 2024 £
<b>Income and endowments from:</b>				
Donations and legacies				
Donations and gifts	2,064	-	2,064	4,350
Membership Fees	21,462	-	21,462	18,902
	<u>23,526</u>	<u>-</u>	<u>23,526</u>	<u>23,252</u>
Charitable activities				
Sponsorship	104,234	-	104,234	114,228
	<u>104,234</u>	<u>-</u>	<u>104,234</u>	<u>114,228</u>
Other				
	200	-	200	-
	<u>200</u>	<u>-</u>	<u>200</u>	<u>-</u>
<b>Total income and endowments</b>	<b>127,960</b>	<b>-</b>	<b>127,960</b>	<b>137,480</b>
<b>Expenditure on:</b>				
Charitable activities				
Conferences and newsletters	56,149	-	56,149	70,308
Application development costs	-	5,068	5,068	-
	<u>56,149</u>	<u>5,068</u>	<u>61,217</u>	<u>70,308</u>
Governance costs				
	-	-	-	127
	<u>-</u>	<u>-</u>	<u>-</u>	<u>127</u>
<b>Total of expenditure on charitable activities</b>	<b>56,149</b>	<b>5,068</b>	<b>61,217</b>	<b>70,435</b>
General administrative costs, including depreciation and amortisation				
Software, IT support and related costs	3,136	-	3,136	5,095
Subscriptions	9,770	-	9,770	5,643
Sundry expenses	31,717	-	31,717	26,500
	<u>44,623</u>	<u>-</u>	<u>44,623</u>	<u>37,238</u>
Legal and professional costs				
Audit/Independent examination fees	1,440	-	1,440	1,160
Management charges	14,222	-	14,222	13,088
	<u>15,662</u>	<u>-</u>	<u>15,662</u>	<u>14,248</u>
<b>Total of expenditure of other costs</b>	<b>60,285</b>	<b>-</b>	<b>60,285</b>	<b>51,486</b>
<b>Total expenditure</b>	<b>116,434</b>	<b>5,068</b>	<b>121,502</b>	<b>121,921</b>
Net gains on investments	-	-	-	-

**UK And Ireland Neuroendocrine Tumour Society Limited**  
**Detailed Statement of Financial Activities**

	11,526	(5,068)	6,458	15,559
<b>Net income</b>				
Transfers between funds	396	(396)	-	-
<b>Net income before other gains/(losses)</b>	11,922	(5,464)	6,458	15,559
Other Gains	-	-	-	-
<b>Net movement in funds</b>	11,922	(5,464)	6,458	15,559
<b>Reconciliation of funds:</b>				
Total funds brought forward	156,995	5,464	162,459	146,900
<b>Total funds carried forward</b>	168,917	-	168,917	162,459